- Biontech boss Ugur Sahin: soon clarity about production quantities for vaccine.
- Biontech wants to deliver vaccine throughout the EU.
- The situation currently looks “not rosy”.
Biontech boss Ugur Sahin assumes that the company will have clarity about the further production quantities for the corona vaccine by the end of January. “ We try, to win new cooperation partners who produce for us. But it is not as if specialized factories were standing around unused all over the world that could produce vaccines of the required quality overnight, “said Sahin (55) the” Spiegel “. “ We’ll have clarity at the end of Januarywhether and how much we can produce more. “
It could get viable results End of month also give to what extent the Biontech vaccine not only Covid-19 diseases, but also Prevents infection. “ We will have data on this around the end of January, at least indirectly,” said the medical director and Biontech co-founder Özlem Türeci the “ Spiegel”.
Nationwide have been good so far 130,000 people vaccinated with the Biontech vaccine against corona. By Thursday morning, 131,626 vaccinations had been reported to the Robert Koch Institute (RKI). 57,406 nursing home residents were among those vaccinated.
Looks “not bright”
Currently, it sees in terms of the total available vaccines against Covid-19 “not rosy” “ Because there are no other approved vaccines and we have to fill this gap with our vaccine,” said Sahin. The vaccine from Biontech and Pfizer was Approved shortly before Christmas in the EU and has been administered for a few days. There are currently no further approvals for corona vaccines in the EU. The international community had ordered vaccine doses from several manufacturers. “There was an assumption that many other companies would come with vaccines. Apparently the impression was: We’ll get enough, it won’t be that badand we have that under control. That surprised me, “said Sahin.
SPD: Spahn has to do more
The idea of the EU and other governments was to put together a basket of different providers, which was a very sensible approach, added Türeci. “ At some point, however, it turned out that many of them cannot deliver on time. Then it was too late to order extensively elsewhere.”
According to the SPD parliamentary group, Health Minister Jens Spahn (CDU) must do more to promote more vaccines. At a summit with all pharmaceutical companies producing in Germany, Spahn had to clarify “which production facilities exist and can be made usable at short notice,” said the parliamentary group manager Carsten Schneider of the German press agency. “The Federal Minister of Health must quickly end the chaos surrounding the delivery and distribution of the vaccine.”
Second vaccination dose later?
Recently there had been a stir about the deliveries of vaccination doses to the federal states. The next batch should now on January 8th arrive. “ We have developed a vaccine against the virus in Germany through government support. It is unacceptable that this vaccine is not even available in the announced quantity after the start of the vaccination,” criticized Schneider.
There is currently a discussion in Germany as to whether the necessary give the second dose later should in order to vaccinate as many people as possible with the scarce supplies. The European approval authority EMA now dampened expectations. Although an upper limit for the time interval between the doses is not explicitly defined, the proof of effectiveness is based on a study in which the administration of the doses at an interval of 19 to 42 days took place, the EMA announced on Friday to the German press agency.
Approach very sensible
The President of the Paul Ehrlich Institute (PEI), Klaus Cichutek, said on Wednesday that from his point of view the previous approach was the same very sensible and correct. Because the corresponding effectiveness and safety data are available.
Teaserbild: © imago images/photothek